IND Swift Laboratories Ltd
NSE:INDSWFTLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (0.9), the stock would be worth ₹-3.66 (103% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -34.5 | ₹137.97 |
0%
|
| 3-Year Average | 0.9 | ₹-3.66 |
-103%
|
| 5-Year Average | 8 | ₹-32.13 |
-123%
|
| Industry Average | 25.6 | ₹-102.15 |
-174%
|
| Country Average | 23.3 | ₹-93 |
-167%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
IND Swift Laboratories Ltd
NSE:INDSWFTLAB
|
11.3B INR | -34.5 | 4.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 30.3 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 21.6 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 22 | 28.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.7 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 11.8 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.3 | 10.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 10 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 8.9 | 16.8 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 15.7 |
| Median | 23.3 |
| 70th Percentile | 34.7 |
| Max | 48 145.1 |
Other Multiples
IND Swift Laboratories Ltd
Glance View
Ind-Swift Laboratories Ltd. engages in the manufacture, development, and market of pharmaceutical ingredients. The company is headquartered in Chandigarh, Chandigarh. The company went IPO on 2002-03-15. The firm operates through the bulk drugs and pharmaceuticals segment. Its business includes Active Pharmaceutical Ingredients (APIs), Advanced Intermediates, and Contract Research and Manufacturing Services (CRAMS). The firm has a product portfolio of approximately 12 therapeutic segments. The company is manufacturing APIs of complex therapies namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Multidisciplinary skills Synthetic Medicinal Chemistry Custom Synthesis Process R&D cGMP Manufacturing Analytical Development Regulatory Support Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. The Company’s products and services include API products, custom chemicals, and impurities. The firm manufacturing facilities are at Derabassi and Jammu Kashmir.
